Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity

International Journal of Hematology

Volumn 74, Issue 3, 2001, Pages 347-351

  Sugio, Yasuhiro ^a   Okamura, Takashi ^a,e   Shimoda, Kazuya ^a   Matsumoto, Masanori ^b   Yagi, Hideo ^b   Ishizashi, Hiromichi ^b   Niho, Yoshiyuki ^a,c   Inaba, Shoichi ^d   Fujimura, Yoshihiro ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c CHIHAYA HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY HOSPITAL   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiplatelet therapy; Autoantibody; Plasma exchange; Thrombotic thrombocytopenic purpura; von Willebrand factor cleaving protease

Indexed keywords

ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G; METALLOPROTEINASE; TICLOPIDINE; VON WILLEBRAND FACTOR DEGRADING PROTEASE; VON WILLEBRAND FACTOR-DEGRADING PROTEASE;

ADULT; ARTICLE; BLOOD; CASE REPORT; HUMAN; IATROGENIC DISEASE; IMMUNOLOGY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; ARTERIAL OCCLUSIVE DISEASES; AUTOANTIBODIES; CASE REPORT; HUMAN; IMMUNOGLOBULIN G; MALE; METALLOENDOPEPTIDASES; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TICLOPIDINE;

EID: 0035491909     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982073     Document Type: Article

References (19)

1. Moschcowitz E. Hyalin thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Path Soc. 1924; 24:21-24.
2. Kakishita E. Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). Int J Hematol. 2000;71:320-327.
3. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1998;78:1456-1461.
4. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thromcytopenic purpura. Blood. 1997;89:3097-3103.
5. Furlan M, Robles R, Solenthaler M, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998;91:2839-2846.
6. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339,1578-1584.
7. Sharis PJ, Canon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
8. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrocloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501-507.
9. Bennet CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med. 1998;128:541-544.
10. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stealing. JAMA. 1999;281:806-810.
11. Bennet CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med. 1999;159:2524-2548.
12. Fujimura Y, Titani K, Holland L, et al. Von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 1986;261:381-385.
13. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980;65:1318-1325.
14. Tsai HM, Chun-Yet Lian E. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
15. Kinoshita S, Yoshioka A, Park Y-D, et al. Upshaw-Schulman syndrome revisited: A concept of congential thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74:101-108.
16. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
17. Tsai HM, Rice R, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000;132: 794-799.
18. Mauro M, Dang C, Raife T, et al. Ticlopidine-linked thrombotic thrombocytopenic purpura: association with endothelial cell apoptosis and disruption of extracellular matrix in vitro and in vivo [abstract]. Blood. 1999;94(suppl 1):646a.
19. Bennet CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342:1773-1777.